Danielle Geraldi-Samara, MD

Early results from Synapticure’s mental healthcare program show real improvements in anxiety, depression, and caregiver support through telehealth

Summary of drug trials for sporadic ALS: qualifications, mechanisms of action, early-stage results, and FDA status

Synapticure prioritizes clinical trial discussions so you can make informed decisions about which trial is best for you

A look at the different blood tests that are drawn before diagnosing ALS and the reasons why we do them

How specialists can help primary care physicians and clinics maintain their heroic patient care efforts for ALS patients

A look at how a virtual clinic optimizes a comprehensive care model for ALS patients

Step-by-step guide to lumbar punctures for a less scary experience

Many patients wonder about Vitamin D supplementation and ALS. Here is the scoop on this unique vitamin.

ALS patients should know of these modalities for symptomatic treatments to improve quality of life and function

A primer on where we stand with available FDA approved disease modifying treatment for ALS

A glance at the cognitive disease Frontotemporal Dementia (FTD) which can underlie the motor symptoms of ALS

A look at the different faces of ALS

How we can help tame anxiety, a common symptom associated with ALS

Synapticure’s Dr. Danielle Geraldi explains how we work hand-in-hand with patients’ existing care teams

Every stride we take towards slowing ALS progression is a step closer to the cure for patients with ALS

Synapticure has opened its doors to those living with Primary Lateral Sclerosis (PLS)

The third FDA approved treatment for ALS, Relyvrio, is now open for enrollment and prescription. Here is a timeline of what you can expect in the coming weeks and how Synapticure can help you through the process.

A new therapy for ALS is on the horizon and here are the details!

My journey as an ALS physician